Einsele, H
Knop, S
Vogel, M
Müller, J
Kropff, M
Metzner, B
Langer, C
Sayer, H
Jung, W
Dürk, H A
Salwender, H
Wandt, H
Bassermann, F
Gramatzki, M
Rösler, W
Wolf, H-H
Brugger, W
Engelhardt, M
Fischer, T
Liebisch, P
Straka, C
Article History
First Online: 15 March 2017
Competing interests
: The authors declare the following: HE: honoraria (Celgene, Janssen); consulting/advisory role (Celgene, Janssen, Novartis, Amgen); Speakers’ bureau (Celgene, Janssen, Novartis, Amgen); research funding (Celgene, Janssen); travel/accommodation/expenses (Celgene, Janssen, Novartis). MV: employment (Janssen-Cilag GmbH). SK: honoraria (Celgene, Janssen); consulting/advisory role (Celgene, Novartis, Onyx). MK: consulting/advisory role (Celgene, Janssen, Onyx); Speakers’ bureau (Celgene, Janssen, Onyx); travel/accommodation/expenses (Celgene, Janssen). BM: consulting/advisory role (Amgen, Sanofi); travel/accommodation/expenses (Celgene, Takeda). H Sayer: consulting/advisory role (Riemser Pharma). H Salwender: honoraria (Janssen); travel/accommodation/expenses (Janssen). FB: travel/accommodation/expenses (Celgene). MG: research funding (Janssen); travel/accommodation/expenses (Janssen). WR: consulting/advisory role (Janssen); travel/accommodation/expenses (Janssen). ME: honoraria (Celgene, Janssen, MSD); consulting/advisory role (Celgene, Janssen, MSD); research funding (Celgene); travel/accommodation/expenses (Celgene). TF: honoraria (Novartis); consulting/advisory role (Novartis). CS: honoraria (Celgene, Janssen, Onyx); consulting/advisory role (Celgene, Janssen, Onyx); research funding (Celgene, Chugai); expert testimony (Celgene, Onyx); travel/accommodation/expenses (Celgene, Onyx). The remaining authors declare no conflict of interest.